Centogene announces appointment of new board member

Dr. Péter Adorján
(PresseBox) ( Rostock, Germany, )
Dr. Péter Adorján has been appointed to the board of Centogene, extending the board to three members.

As Chief Business Development Officer, Dr. Péter Adorján will start his work on February 9th. He will be in charge of expanding Centogene's rich portfolios and bringing them to the market.

"Péter has nearly two decades of broad experience across the health care and IT industries which will bring valuable perspectives to our board and the company in general," explained Professor Arndt Rolfs, CEO and founder.

After earning his PhD in informatics, focusing on computational neuroscience and machine learning, Péter Adorján joined Epigenomics AG. There he established and led the Biostatistics Department as VP Information Sciences and later took over as VP Manufacturing. In these positions he played a key role in creating multi-year joint ventures with large pharmaceutical companies as well as in IVD product development. He then served as a Senior Consultant at McKinsey & Company Inc. in the Business Technology Office. As Global Competence Center Manager and Director Portfolio at T-Systems and Unisys, he was responsible for the IT services portfolio and go-to-market on a European scale. Péter is passionate about generating growth and value through knowledge enabled products and services. He has published several peer-reviewed scientific papers and holds multiple patents.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.